Prostate Cancer

The majority of patients with prostate cancer treated with an enzalutamide or leuprolide acetate regimen recovered their testosterone levels.

Patients with mCRPC enrolled in the phase 3 TALAPRO-2 trial harboring TMPRSS2-ERG fusions in ctDNA had a distinct tumor molecular profile vs those without.

Talazoparib plus enzalutamide improved rPFS vs placebo plus enzalutamide in patients with mCRPC with or without AR alterations.

No complete or partial pathologic responses were achieved with neoadjuvant niraparib in patients with DDR-deficient prostate cancer following surgery.

Experts highlight the top presentations to watch for at the 2025 AUA Annual Meeting.

Evan Y. Yu, MD, discusses the clinical evolution of radiopharmaceuticals for patients with mCRPC and how PSMA PET may evolve to monitor treatment response.

Nataliya Mar, MD, discusses clinical considerations when selecting between the wide range of androgen receptor pathway inhibitors in prostate cancer.

Nogapendekin alfa inbakicept sBLA in NMIBC has been filed to FDA for review, a bexmarilimab combination elicits responses in MDS, and more from OncLive.

Evan Y. Yu, MD, discusses future directions for biomarker research and targeted therapy development for patients with castration-resistant prostate cancer.

Marc R. Matrana, MD, discusses the evolving frontline treatment landscape for advanced metastatic prostate cancer.

Evan Y. Yu, MD, discusses PARP inhibitor treatment selection and sequencing for patients with metastatic castration-resistant prostate cancer.

Yung Lyou, MD, discusses FDA-approved isotope therapies and the development of novel therapies in the castration-resistant prostate cancer space.

Apalutamide reduced the risk of death by over 20% vs enzalutamide and abiraterone acetate, respectively, in metastatic castration-sensitive prostate cancer.

Michael J. Morris, MD, discusses data from the PSMAfore trial that supported the FDA expanded approval of lutetium Lu 177 vipivotide tetraxetan in mCRPC.

ARANOTE data underscore that combining darolutamide with ADT benefits patients with mHSPC irrespective of whether they also receive docetaxel.

Michael J. Morris, MD, discusses the FDA expanded approval of lutetium Lu 177 vipivotide tetraxetan in PSMA-positive mCRPC.

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, ovarian cancer, prostate cancer, breast cancer, and follicular lymphoma.

Here is your snapshot for all therapeutic options that were approved by the FDA in March 2025 spanning tumor types.

Joan Carles Galceran, MD, PhD, discusses the safety of adding darolutamide to ADT and docetaxel in older patients with mHSPC.

The EMA’s CHMP has issued a positive opinion for the denosumab biosimilars Osvyrti and Jubereq for the same indications as the reference products.

Michael J. Morris, MD, discusses the FD expanded approval of lutetium Lu 177 vipivotide tetraxetan for the treatment of patients with PSMA-positive mCRPC.

Tanya B. Dorff, MD, highlights the safety profile of lutetium Lu 177 vipivotide tetraxetan in patients with mCRPC with impaired renal function.

The FDA cleared therapeutic options in pNETs/epNETs, MIBC, and mCRPC; experts highlight top abstracts ahead of 2025 EBMT; and more from OncLive.

The FDA has expanded the indication for lutetium Lu 177 vipivotide tetraxetan for use in additional patients with PSMA-positive metastatic castration-resistant prostate cancer.

Alicia Morgans, MD, MPH, discusses how a lack of PSA doubling time documentation may lead to undertreatment in high-risk BCR prostate cancer.